<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="85534">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01699750</url>
  </required_header>
  <id_info>
    <org_study_id>M-12-043 / ID11-59</org_study_id>
    <nct_id>NCT01699750</nct_id>
  </id_info>
  <brief_title>Comparative In-Vivo Wetting Characteristics of Silicone Hydrogel Materials With Selected Lens Care Systems</brief_title>
  <official_title>Comparative In-Vivo Wetting Characteristics of Silicone Hydrogel Materials With Selected Lens Care Systems</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <authority>United Kingdom: Research Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the lipid uptake, wetting characteristics, and
      visual performance of AIR OPTIX® AQUA and ACUVUE® OASYS® with HYDRACLEAR® contact lenses
      when used in conjunction with two contact lens care systems, OPTI-FREE® PUREMOIST® MPDS and
      BIOTRUE®.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will be divided into two phases, a pre-investigational screening phase and an
      investigational phase. During the pre-investigational screening phase, all participants will
      use PureVision contact lenses and ReNu Multiplus multipurpose solution per manufacturers'
      guidelines for 30 days. Eligible participants will continue into the investigational phase
      and will be randomly assigned to wear Air Optix Aqua or Oasys lenses with two months
      randomized crossover of contact lens care (one month each of Opti-Free PureMoist MPDS and
      Biotrue MPS).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">November 2013</completion_date>
  <primary_completion_date type="Actual">November 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject)</study_design>
  <primary_outcome>
    <measure>Ex-Vivo Lipid Uptake</measure>
    <time_frame>Day 30</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Non-Invasive Tear Film Break Up Time</measure>
    <time_frame>Day 30</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-Controlled Visual Acuity</measure>
    <time_frame>Day 30</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective Comfort</measure>
    <time_frame>Day 30</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dryness</measure>
    <time_frame>Day 30</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">109</enrollment>
  <condition>Myopia</condition>
  <condition>Astigmatism</condition>
  <condition>Refractive Error</condition>
  <arm_group>
    <arm_group_label>Lotrafilcon B with Opti-Free Puremoist, then Biotrue</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lotrafilcon B contact lenses with OPTI-FREE PUREMOIST for 30 days, followed by BIOTRUE for an additional 30 days.  A fresh pair of lenses was dispensed for each solution.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lotrafilcon B with Biotrue, then Opti-Free Puremoist</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lotrafilcon B contact lenses with BIOTRUE for 30 days, followed by OPTI-FREE PUREMOIST for an additional 30 days.  A fresh pair of lenses was dispensed for each solution.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Senofilcon A with Opti-Free Puremoist, then Biotrue</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Senofilcon A contact lenses with OPTI-FREE PUREMOIST for 30 days, followed by BIOTRUE for an additional 30 days.  A fresh pair of lenses will be dispensed for each solution, with biweekly replacement.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Senofilcon A with Biotrue, then Opti-Free Puremoist</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Senofilcon A with BIOTRUE for 30 days, followed by OPTI-FREE PUREMOIST for an additional 30 days.  A fresh pair of lenses will be dispensed for each solution, with biweekly replacement.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Lotrafilcon B contact lenses (AIR OPTIX AQUA)</intervention_name>
    <description>Silicone hydrogel contact lenses worn on a daily wear basis and used with OPTI-FREE PUREMOIST or BIOTRUE lens care systems, 30 days each system, during Phase Two (Investigational Phase)</description>
    <arm_group_label>Lotrafilcon B with Opti-Free Puremoist, then Biotrue</arm_group_label>
    <arm_group_label>Lotrafilcon B with Biotrue, then Opti-Free Puremoist</arm_group_label>
    <other_name>AIR OPTIX® AQUA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Senofilcon A contact lenses (ACUVUE OASYS with HYDRACLEAR)</intervention_name>
    <description>Silicone hydrogel contact lenses worn on a daily wear basis and used with OPTI-FREE PUREMOIST or BIOTRUE lens care systems, 30 days each system, during Phase Two (Investigational Phase).  Contact lenses replaced biweekly.</description>
    <arm_group_label>Senofilcon A with Opti-Free Puremoist, then Biotrue</arm_group_label>
    <arm_group_label>Senofilcon A with Biotrue, then Opti-Free Puremoist</arm_group_label>
    <other_name>ACUVUE® OASYS® with HYDRACLEAR®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OPTI-FREE PUREMOIST Multipurpose Disinfecting System (MPDS) contact lens care system</intervention_name>
    <description>Contact lens care system used with AIR OPTIX AQUA and ACUVUE OASYS WITH HYDRACLEAR contact lenses, 30 days each, during Phase Two (Investigational Phase)</description>
    <arm_group_label>Lotrafilcon B with Opti-Free Puremoist, then Biotrue</arm_group_label>
    <arm_group_label>Lotrafilcon B with Biotrue, then Opti-Free Puremoist</arm_group_label>
    <arm_group_label>Senofilcon A with Opti-Free Puremoist, then Biotrue</arm_group_label>
    <arm_group_label>Senofilcon A with Biotrue, then Opti-Free Puremoist</arm_group_label>
    <other_name>OPTI-FREE® PUREMOIST® MPDS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>BIOTRUE contact lens care system</intervention_name>
    <description>Contact lens care system used with AIR OPTIX AQUA and ACUVUE OASYS WITH HYDRACLEAR contact lenses, 30 days each, during Phase Two (Investigational Phase)</description>
    <arm_group_label>Lotrafilcon B with Opti-Free Puremoist, then Biotrue</arm_group_label>
    <arm_group_label>Lotrafilcon B with Biotrue, then Opti-Free Puremoist</arm_group_label>
    <arm_group_label>Senofilcon A with Opti-Free Puremoist, then Biotrue</arm_group_label>
    <arm_group_label>Senofilcon A with Biotrue, then Opti-Free Puremoist</arm_group_label>
    <other_name>BIOTRUE®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Balafilcon A contact lenses (PureVision)</intervention_name>
    <description>Silicone hydrogel contact lenses worn on a daily wear basis for 30 days during Phase One (Pre-Investigational Phase).</description>
    <arm_group_label>Lotrafilcon B with Opti-Free Puremoist, then Biotrue</arm_group_label>
    <arm_group_label>Lotrafilcon B with Biotrue, then Opti-Free Puremoist</arm_group_label>
    <arm_group_label>Senofilcon A with Opti-Free Puremoist, then Biotrue</arm_group_label>
    <arm_group_label>Senofilcon A with Biotrue, then Opti-Free Puremoist</arm_group_label>
    <other_name>PureVision</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ReNu Multiplus contact lens care system</intervention_name>
    <description>Contact lens care system used for 30 days during Phase One (Pre-Investigational Phase)</description>
    <arm_group_label>Lotrafilcon B with Opti-Free Puremoist, then Biotrue</arm_group_label>
    <arm_group_label>Lotrafilcon B with Biotrue, then Opti-Free Puremoist</arm_group_label>
    <arm_group_label>Senofilcon A with Opti-Free Puremoist, then Biotrue</arm_group_label>
    <arm_group_label>Senofilcon A with Biotrue, then Opti-Free Puremoist</arm_group_label>
    <other_name>ReNu Multiplus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Read and understand the Participant Information Sheet;

          -  Read, sign, and date the Informed Consent;

          -  Be a current silicone hydrogel contact lens wearer using the contact lenses under a
             frequent replacement (bi-weekly or monthly) daily wear modality;

          -  Be classified as symptomatic and a depositor at the end of the replacement period
             according to protocol-specified criteria;

          -  Agree to wear study contact lenses as directed for the duration of the study and
             maintain the appointment schedule;

          -  Best corrected visual acuity of 6/9 or better in each eye;

          -  Normal eyes with the exception of the need for visual correction;

          -  Other protocol-defined inclusion criteria may apply.

        Exclusion Criteria:

          -  Known sensitivity or intolerance to any of the contact lenses or contact lens care
             products to be used;

          -  Monocular vision (only one eye with functional vision or only one eye fitted with
             contact lenses);

          -  Use of systemic medication which might interfere with contact lens wear or produce
             dry eye side effects;

          -  Systemic disease which might interfere with contact lens wear or produce dry eye side
             effects;

          -  Systemic or ocular allergies which might interfere with contact lens wear;

          -  Ocular disease which might interfere with contact lens wear;

          -  Active ocular infection;

          -  Use of any concomitant topical ocular medications during the study period;

          -  Previous ocular surgery;

          -  Pregnant, planning to become pregnant, or lactating at the time of enrollment;

          -  Participation in an investigational drug or device study within 30 days of entering
             this study;

          -  Other protocol-defined exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jami Kern, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Alcon Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Contact Alcon Call Center at 1-888-451-3937 for Trial Locations</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>April 18, 2014</lastchanged_date>
  <firstreceived_date>October 2, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>contact lenses</keyword>
  <keyword>contact lens solution</keyword>
  <keyword>myopia</keyword>
  <keyword>astigmatism</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Astigmatism</mesh_term>
    <mesh_term>Myopia</mesh_term>
    <mesh_term>Refractive Errors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Contact Lens Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
